ERK: a double-edged sword in cancer. ERK-dependent apoptosis as a potential therapeutic strategy for cancer

R Sugiura, R Satoh, T Takasaki - Cells, 2021 - mdpi.com
The RAF/MEK/ERK signaling pathway regulates diverse cellular processes as exemplified
by cell proliferation, differentiation, motility, and survival. Activation of ERK1/2 generally …

[HTML][HTML] Broad targeting of resistance to apoptosis in cancer

RM Mohammad, I Muqbil, L Lowe, C Yedjou… - Seminars in cancer …, 2015 - Elsevier
Apoptosis or programmed cell death is natural way of removing aged cells from the body.
Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks …

NCCN guidelines insights: colon cancer, version 2.2018

AB Benson, AP Venook, MM Al-Hawary… - Journal of the National …, 2018 - jnccn.org
The NCCN Guidelines for Colon Cancer provide recommendations regarding diagnosis,
pathologic staging, surgical management, perioperative treatment, surveillance …

E3 ligases and deubiquitinating enzymes regulating the MAPK signaling pathway in cancers

HB Park, KH Baek - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2022 - Elsevier
The mitogen-activated protein kinase (MAPK) signaling pathway is the primary regulatory
module of various cellular processes such as cell proliferation, differentiation, and stress …

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

L Santarpia, SM Lippman… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: The MAPK pathway comprises several key signaling components and
phosphorylation events that play a role in tumorigenesis. These activated kinases transmit …

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses

J Haroche, F Charlotte, L Arnaud… - Blood, The Journal …, 2012 - ashpublications.org
Histiocytoses are rare disorders of unknown origin with highly heterogeneous prognosis.
BRAF mutations have been observed in Langerhans cell histiocytosis (LCH). We …

[HTML][HTML] Resistance to BRAF-targeted therapy in melanoma

RJ Sullivan, KT Flaherty - European journal of cancer, 2013 - Elsevier
BRAF mutations are identified in 40–50% of patients with melanoma. Treatment of these
patients with either of two BRAF inhibitors (vemurafenib, dabrafenib) or the MEK inhibitor …

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

M Schmidinger, CC Zielinski, UM Vogl… - Journal of clinical …, 2008 - ascopubs.org
Purpose Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) that have considerable
efficacy in metastatic renal cell carcinoma. TKI-associated cardiotoxicity was reported in …

[HTML][HTML] BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies

CN Clarke, ES Kopetz - Journal of Gastrointestinal Oncology, 2015 - ncbi.nlm.nih.gov
Despite new and more effective cytotoxic chemotherapy, limitations to conventional agents
have been reached in a subset of patients with advanced colorectal cancer (CRC). The …

BRAF-mutated non-small cell lung cancer: current treatment status and future perspective

N Yan, S Guo, H Zhang, Z Zhang, S Shen, X Li - Frontiers in oncology, 2022 - frontiersin.org
V-Raf murine sarcoma viral oncogene homolog B (BRAF) kinase, which was encoded by
BRAF gene, plays critical roles in cell signaling, growth, and survival. Mutations in BRAF …